Table 2. Percentages of Discontinuation by Reason.
| Setting | Treatment discontinuation, median (IQR), % | ||||
|---|---|---|---|---|---|
| Progression and death | P value | Adverse events and withdrawal | P value | Other | |
| Overall | |||||
| Adjuvant | 7.5 (2.9-21.2) | <.001 | 21.4 (17.7-29.4) | .01 | 2.3 (0.7-4.2) |
| Metastatic | 46.5 (30.4-54.5) | 15.9 (9.7-21.3) | 1.7 (0.5-3.4) | ||
| Checkpoint inhibitors | |||||
| Adjuvant | 25.5 (21.7-27.3) | .01 | 21.4 (18.6-31.3) | .01 | 1.7 (0.9-2.3) |
| Metastatic | 45.7 (30.3-59.3) | 15.2 (9.9-19.5) | 2.0 (0.6-3.2) | ||
| Cytotoxic | |||||
| Adjuvant | 1.8 (1.3-5.1) | .03 | 16.6 (12.2-23.3) | .07 | 1.5 (0-6.1) |
| Metastatic | 27.6 (13.2-47.4) | 25.5 (19.8-28.8) | 1.2 (0-3.0) | ||
| Targeted | |||||
| Adjuvant | 7.1 (3.5-15.0) | <.001 | 27.7 (19.6-32.3) | <.001 | 3.3 (0.9-5.2) |
| Metastatic | 48.3 (45.5-54.0) | 14.0 (9.0-16.5) | 2.3 (1.0-3.4) | ||